Produced By Deanna Utroske, 2
This month, multinational bioprinting technologies company Cellink announced having reached a deal to acquire Cytena for €30.25 million. The Freiburg, Germany – based venture specialises in single-cell printing technology. And the deal will expand Cellink’s capabilities in both pharma and cosmetics.
Cellink got its start in 2016 and is headquartered in Boston, Massachusetts, (in the US) where a lot of biotech businesses are located. The company makes and commercializes bioprinting technologies for use in academic research and industry. Bioprinting is essentially 3-dimentional printing technology that incorporates live cells and is used to create tissue and other components.
The human vaginal mucosa is comprised of a protective multilayered epithelium with a squamous, stratified…
Veganism is no longer just a dietary choice; it’s a full lifestyle movement that influences…
The European Commission (EC) is hosting a free, one-hour webinar, “When Beauty Meets Green: The…